133 related articles for article (PubMed ID: 16509763)
1. Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers.
Dhawan S; Singh B; Garg SK; Hota D; Dash RJ; Singla AK; Sinha VR
Clin Pharmacokinet; 2006; 45(3):317-24. PubMed ID: 16509763
[TBL] [Abstract][Full Text] [Related]
2. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
Ghosh A; Bhaumik UK; Bose A; Mandal U; Gowda V; Chatterjee B; Chakrabarty US; Pal TK
Biol Pharm Bull; 2008 Oct; 31(10):1946-51. PubMed ID: 18827360
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus.
Chung M; Kourides I; Canovatchel W; Sutfin T; Messig M; Chaiken RL
J Clin Pharmacol; 2002 Jun; 42(6):651-7. PubMed ID: 12043953
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs.
Kulkarni R; Yumibe N; Wang Z; Zhang X; Tang CC; Ruterbories K; Cox A; McCain R; Knipp GT
J Pharm Sci; 2012 Nov; 101(11):4327-36. PubMed ID: 22899546
[TBL] [Abstract][Full Text] [Related]
5. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.
Foster RH; Plosker GL
Pharmacoeconomics; 2000 Sep; 18(3):289-306. PubMed ID: 11147395
[TBL] [Abstract][Full Text] [Related]
6. [Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network].
Zhang ZH; Wang Y; Wu WF; Zhao X; Sun XC; Wang HQ
Yao Xue Xue Bao; 2012 Dec; 47(12):1687-95. PubMed ID: 23460977
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
[TBL] [Abstract][Full Text] [Related]
8. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
[TBL] [Abstract][Full Text] [Related]
9. A bioequivalence study of two brands of glipizide tablets.
Kobylińska M; Bukowska-Kiliszek M; Barlińska M; Sobik B; Kobylińska K
Acta Pol Pharm; 2000; 57(2):101-4. PubMed ID: 10934787
[TBL] [Abstract][Full Text] [Related]
10. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
12. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
13. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
He L; Wickremasingha P; Lee J; Tao B; Mendell-Harary J; Walker J; Wight D
J Clin Pharmacol; 2014 Jan; 54(1):61-9. PubMed ID: 24019110
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
16. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
Hsieh SH; Lin JD; Cheng HY; Ho C; Liou MJ
Clin Ther; 2006 Sep; 28(9):1318-26. PubMed ID: 17062305
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
[TBL] [Abstract][Full Text] [Related]
18. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing.
Verma RK; Garg S
J Pharm Biomed Anal; 2005 Jul; 38(4):633-44. PubMed ID: 15967291
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses.
Kradjan WA; Takeuchi KY; Opheim KE; Wood FC
Pharmacotherapy; 1995; 15(4):465-71. PubMed ID: 7479199
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
Darwish M; Chang S; Hellriegel ET
Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
